Padagis is looking to capitalize on 180 days of competitive generic therapy exclusivity for its latest product launch, after introducing the first US rival to Uceris (budesonide) 2mg rectal foam.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?